How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,282 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. HFR A-equilibrium on Cardiovascular Stability

less than 2 ml/min/1.73 m2 native fistula or central venous catheter with blood flow rate greater than 250 ml/min Exclusion Criteria: Life expectancy less than 1 year solid active neoplasm pregnancy major event in the previous 3 months (ictus, myocardial infarction, cachexia) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor (...) HFR A-equilibrium on Cardiovascular Stability HFR A-equilibrium on Cardiovascular Stability - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. HFR A-equilibrium on Cardiovascular Stability (AIMS) The safety

2011 Clinical Trials

222. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. (PubMed)

Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. To investigate growth differentiation factor (GDF)-15 at hospital discharge for assessment of the risk of death, recurrent myocardial infarction (MI), and congestive heart failure, and to determination of whether these risks can be modified by statins.GDF-15 is a transforming growth factor-β-related cytokine induced in response to tissue injury

Full Text available with Trip Pro

2011 Arteriosclerosis, thrombosis, and vascular biology Controlled trial quality: uncertain

223. A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery; rationale and design of DECREASE-XIII. (PubMed)

of heart rate outside the target window during infusion of the study drug. Secondary outcome measures will be the efficacy parameters of occurrence of cardiac ischaemia, troponin T release, myocardial infarction and cardiac death within 30 days after surgery and safety parameters such as the occurrence of stroke and hypotension.This study will provide data on the efficacy of esmolol titration in chronic beta-blocker users for tight heart-rate control and reduction of ischaemia in patients undergoing (...) A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery; rationale and design of DECREASE-XIII. This article describes the rationale and design of the DECREASE-XIII trial, which aims to evaluate the potential of esmolol infusion, an ultra-short-acting beta-blocker, during surgery as an add-on to chronic low-dose beta-blocker therapy to maintain perioperative haemodynamic stability during major vascular surgery.A double-blind, placebo

Full Text available with Trip Pro

2011 European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery Controlled trial quality: predicted high

224. A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. (PubMed)

I6WP63U32H Acenocoumarol AIM IM Acenocoumarol therapeutic use Blood Coagulation drug effects Blood Coagulation Tests Coronary Disease drug therapy Coumarins therapeutic use Female Humans Male Middle Aged Myocardial Infarction prevention & control 1969 10 1 1969 10 1 0 1 1969 10 1 0 0 ppublish 5378105 (...) A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. 5378105 1970 05 04 2013 11 21 0001-6101 186 4 1969 Oct Acta medica Scandinavica Acta Med Scand A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. 283-8 Breed W P WP van Hooff J P JP Haanen C C eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Sweden Acta Med Scand 0370330 0001-6101 0 Coumarins

1970 Acta Medica Scandinavica Controlled trial quality: uncertain

225. Myocardial infarction

Myocardial infarction Myocardial infarction - Wikipedia Myocardial infarction From Wikipedia, the free encyclopedia "Heart attack" redirects here. For other uses, see . Myocardial infarction Other names Acute myocardial infarction (AMI), heart attack Diagram showing the by the two major blood vessels, the and (labelled LCA and RCA). A myocardial infarction (2) has occurred with blockage of a branch of the left coronary artery (1). , Symptoms , , nausea, , , ; arm, neck, back, jaw, or stomach (...) pain , , , Causes Usually , , , , , (ECGs), blood tests, Treatment , Medication , , Prognosis STEMI 10% risk of death (developed world) Frequency 15.9 million (2015) Myocardial infarction ( MI ), commonly known as a heart attack , occurs when decreases or stops to a part of the , causing damage to the . The most common symptom is or discomfort which may travel into the shoulder, arm, back, neck, or jaw. Often it occurs in the center or left side of the chest and lasts for more than a few minutes

2012 Wikipedia

226. Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice (PubMed)

Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice Prolonged inflammatory response is associated with left ventricular (LV) dysfunction and adverse remodeling following myocardial infarction (MI). IL-10 inhibits inflammation by suppressing HuR-mediated mRNA stabilization of proinflammatory cytokines. Here we report that following MI, IL-10(-/-) mice showed exaggerated LV dysfunction, fibrosis (...) , and cardiomyocyte apoptosis. Short-hairpin RNA (shRNA)-mediated knockdown of HuR in the myocardium significantly reversed MI-induced LV dysfunctions and LV remodeling. HuR knockdown significantly reduced MI-induced cardiomyocyte apoptosis concomitant with reduced p53 expression. Moreover, HuR knockdown significantly reduced infarct size and fibrosis area, which in turn was associated with decreased TGF-beta expression. In vitro, stable knockdown of HuR in mouse macrophage cell line RAW 264.7 corroborated

Full Text available with Trip Pro

2010 The FASEB Journal

227. Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia

, as documented by echocardiography Planned staged treatment of CAD or other intervention on the heart Platelet count < 100,000/mm3 WBC < 2,000/mm3 TIA or stroke within 90 days prior to randomization ICD shock within 30 days of randomization Any condition requiring immunosuppressive medication A high-risk acute coronary syndrome (ACS) or a myocardial infarction within 60 days prior to randomization Revascularization within 60 days prior to randomization Inability to walk on a treadmill except for class IV (...) Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2012 Clinical Trials

228. Desipramine Pretreatment Improves Sympathetic Remodeling and Ventricular Fibrillation Threshold after Myocardial Ischemia (PubMed)

Desipramine Pretreatment Improves Sympathetic Remodeling and Ventricular Fibrillation Threshold after Myocardial Ischemia Abnormal increase in sympathetic nerve sprouting was responsible for the ventricular arrhythmogenesis after myocardial infarction. This study investigated whether the norepinephrine transporter inhibitor, desipramine, can modulate sympathetic remodeling and ventricular fibrillation threshold (VFT) after myocardial ischemia-reperfusion. Rats were administered desipramine (0.8 (...)  mg/kg, i.v.) before or after myocardial ischemia. VFT, infarct size, tyrosine hydroxylase (TH) and growth-associated protein 43 (GAP43)-positive nerve fibers were measured after one week. The VFT of preischemic treatment group was 11.0 ± 2.65 V and significantly higher than that of control ischemic group (7.2 ± 1.30 V, P < 0.05). Infarct size in the preischemic treatment group (23.3 ± 2.4%) was significantly lower than that in the control ischemic group (30.8 ± 1.3%, P < 0.05) and the delayed

Full Text available with Trip Pro

2012 Journal of Biomedicine and Biotechnology

229. Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI)

Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI) Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI) (VIRHISTAMI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2010 Clinical Trials

230. Impact of statin pretreatment on the incidence of plaque rupture in ST-elevation acute myocardial infarction. (PubMed)

Impact of statin pretreatment on the incidence of plaque rupture in ST-elevation acute myocardial infarction. Several studies in experimental animals have shown that statins stabilize atheromatous plaques by increasing fibrous-cap thickness. However, direct evidence linking the use of statins to the incidence of plaque rupture in humans is lacking. We investigated whether statin treatment before the onset of ST-elevation myocardial infarction (STEMI) influences the incidence of plaque rupture

2010 Atherosclerosis

231. Acute myocardial infarction hospitalization in the United States, 1979 to 2005. (PubMed)

Survey and US civilian population from 1979 to 2005, aggregated by 3-year groupings. We also assessed comorbid, complications, cardiac procedure use, and in-hospital case-fatality rates.Age-adjusted hospitalization rate for acute myocardial infarction identified by primary International Classification of Diseases code was 215 per 100,000 people in 1979-1981 and increased to 342 in 1985-1987. Thereafter, the rate stabilized for the next decade and then declined slowly after 1996 to 242 in 2003-2005 (...) Acute myocardial infarction hospitalization in the United States, 1979 to 2005. We reported earlier that there was no decline of acute myocardial infarction hospitalization from 1988 to 1997. We now extend these observations to document trends in acute myocardial infarction hospitalization rates and in-hospital case-fatality rates for 27 years from 1979 to 2005.We determined hospitalization rates for acute myocardial infarction by age and gender using data from the National Hospital Discharge

2010 American Journal of Medicine

232. Reproducibility in Serial C-Reactive Protein and Interleukin-6 Measurements in Post-Myocardial Infarction Patients: Results from the AIRGENE Study. (PubMed)

Reproducibility in Serial C-Reactive Protein and Interleukin-6 Measurements in Post-Myocardial Infarction Patients: Results from the AIRGENE Study. Among the numerous emerging biomarkers, high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) have received widespread interest, and a large database has been accumulated on their potential role as predictors of cardiovascular risk. The concentrations of inflammatory biomarkers, however, are influenced, among other things (...) , by physiological variation, which is the natural within-individual variation occurring over time. Implementation of hsCRP and IL-6 measurement into clinical practice requires data on the reliability of such measurements.We serially measured hsCRP and IL-6 concentrations in up to 6 blood samples taken at monthly intervals from 200 post-myocardial infarction patients who participated in the AIRGENE study.The mean (SD) of the ln-transformed plasma concentrations (in milligrams per liter for hsCRP and nanograms

Full Text available with Trip Pro

2010 Clinical Chemistry

233. Strategies of Revascularization in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Disease

between 40 and 60% of patients with ST-segment elevation myocardial infarction (STEMI) and has been associated to a worse prognosis. Multivessel revascularization offers a myriad of potential advantages as enhance of the collateral blood flow, greater myocardial salvage, the stabilization of other lesions that can be potentially vulnerable, and the achievement of a complete revascularization, factor that is associated with a better prognosis. On the other hand, the prolongation of procedural duration (...) Strategies of Revascularization in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Disease Strategies of Revascularization in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2010 Clinical Trials

234. Cytokine Combination Therapy with Erythropoietin and Granulocyte Colony Stimulating Factor in a Porcine Model of Acute Myocardial Infarction (PubMed)

Cytokine Combination Therapy with Erythropoietin and Granulocyte Colony Stimulating Factor in a Porcine Model of Acute Myocardial Infarction Erythropoietin (EPO) and granulocyte colony stimulating factor (GCSF) have generated interest as novel therapies after myocardial infarction (MI), but the effect of combination therapy has not been studied in the large animal model. We investigated the impact of prolonged combination therapy with EPO and GCSF on cardiac function, infarct size, and vascular (...) density after MI in a porcine model.MI was induced in pigs by a 90 min balloon occlusion of the left anterior descending coronary artery. 16 animals were treated with EPO+GCSF, or saline (control group). Cardiac function was assessed by echocardiography and pressure-volume measurements at baseline, 1 and 6 weeks post-MI. Histopathology was performed 6 weeks post-MI.At week 6, EPO+GCSF therapy stabilized left ventricular ejection fraction, (41 ± 1% vs. 33 ± 1%, p < 0.01) and improved diastolic function

Full Text available with Trip Pro

2010 Cardiovascular Drugs and Therapy

235. Leucine125Valine (Leu125Val) Gene Polymorphism of Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) and Myocardial Infarction in Indian Population (PubMed)

Leucine125Valine (Leu125Val) Gene Polymorphism of Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) and Myocardial Infarction in Indian Population Platelet-endothelial cell adhesion molecule-1 (PECAM-1) has role in atherosclerotic plaque development as well as in thrombosis leading to myocardial infarction (MI). Present study was aimed to analyse the association of PECAM-1 Leu125Val gene polymorphism with MI in Indian population. Subjects included healthy individuals as control (N = 116 (...) ) and MI patients (N = 100) divided into two groups; MI patients at presentation of the acute event (MI-Group-1, N = 46) and patients with recent event of MI stabilized with treatment 4.5 days from their symptoms (MI-Group-2, N = 54). The difference in the distribution of Leu125Val genotype frequencies of controls and patients did not reach statistical significance. However Leu allele frequency (0.57) was more associated with MI patients as compared to control (0.504). sPECAM-1 levels were

Full Text available with Trip Pro

2010 Indian Journal of Clinical Biochemistry

236. [Efficiency of ACE inhibitors, beta adrenoblocker and antihypoxant in the phase of stationary rehabilitation of patients with myocardial infarction working in environmentally unfriendly conditions]. (PubMed)

[Efficiency of ACE inhibitors, beta adrenoblocker and antihypoxant in the phase of stationary rehabilitation of patients with myocardial infarction working in environmentally unfriendly conditions]. The aim of this work was to study effect of fosinopril combined with propranolol or cytomack on ecoendotoxicosis, size of myocardial infarction (MI), left ventricular (LV) systolic function, and clinical picture of stationary phase MI in patients working in environmentally unfriendly conditions. 42 (...) functions (ESV, EDV, EF), size of MI (total ST, AST, total Rh), and clynical symptoms. It was shown that patients working in environmentally unfriendly conditions were characterized by high degree of PSD. In group 1 they exhibited reduction of PSD, total ST, AST, ESV, EDV and increase of total Rh and EF. Decreased systolic and diastolic AP did not lead to clinically significant hypotension. Patients of group 2 showed stabilization of AP, decrease of PSD, total ST, AST, ESV, EDV and increase of total Rh

2010 Klinicheskaia meditsina Controlled trial quality: uncertain

237. On Versus Off Pump Myocardial Revascularization Study

, prospective, randomized, parallel, trial.Patients indicated for elective or urgent isolated coronary artery bypass graft with additive European System for Cardiac Operative Risk Evaluation ≥ 6 were enrolled. Patients in cardiogenic shock were excluded. Patients were randomly assigned either to coronary artery bypass surgery with cardiopulmonary bypass (ON arm) or to off-pump coronary artery bypass graft (OFF arm). The composite primary end point included operative mortality, myocardial infarction, stroke (...) : Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: ON Pump vs OFF Pump Myocardial Revascularization in High Risk Patients: a Randomized Study Study Start Date : September 2006 Actual Primary Completion Date : June 2010 Actual Study Completion Date : June 2011 Arms and Interventions Go to Arm Intervention/treatment Experimental: Off-pump bypass surgery Off-pump coronary artery bypass graft (OPCAB) using mandatory a stabilization device and advisable

2011 Clinical Trials

238. Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment

Association functional class II - IV) despite stabile optimal medical therapy. Wide QRS ≥ 120 milliseconds on standard ECG. LV systolic dysfunction (EF ≤ 35%). Written informed consent. Accepted for CRT-P or CRT-D treatment Exclusion Criteria: Life expectancy < 12 months. Recent myocardial infarction (< 3 months). Significant valve disease Chronic atrial fibrillation Pregnancy Severely impaired renal function (estimated glomerular filtration rate (eGFR) < 30 ml/min) Unable to give written informed consent (...) Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2011 Clinical Trials

239. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. (PubMed)

to standard of care, including lipid-lowering and antiplatelet therapies.STABILITY is a randomized, placebo-controlled, double-blind, international, multicenter, event-driven trial. The study has randomized 15,828 patients with chronic coronary heart disease (CHD) receiving standard of care to darapladib enteric-coated (EC) tablets, 160 mg or placebo.The primary end point is the composite of major adverse cardiovascular events (MACE): CV death, nonfatal myocardial infarction, and nonfatal stroke. The key (...) Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Elevated plasma levels of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) are associated with increased risk of cardiovascular (CV) events. Direct inhibition of this proinflammatory enzyme with darapladib may benefit CV patients when given as an adjunct

2010 American heart journal Controlled trial quality: predicted high

240. High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 Stability Before and After Stroke and Myocardial Infarction. (PubMed)

High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 Stability Before and After Stroke and Myocardial Infarction. High-sensitivity C-reactive protein (hsCRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) are hypothesized to be biomarkers of systemic inflammation and risk of myocardial infarction (MI) and stroke. Little is known, however, about the stability of these markers over time, and in particular, about the effects of acute vascular events (...) on these marker levels.Serum samples were collected at 4 annual intervals in 52 stroke-free participants from the Northern Manhattan Study (NOMAS) and assayed for hsCRP and Lp-PLA2 mass and activity levels using standard techniques. Log transformation of levels was performed as needed to stabilize the variance. Stability of marker levels over time was assessed using random effects models unadjusted and adjusted for demographics and other risk factors. In addition, samples from 37 initially stroke-free

Full Text available with Trip Pro

2009 Stroke

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>